Larry Bock

Serial entrepreneur and seed stage high technology and life sciencesventure capitalist

Founded, co-founded or provided early stage financing to 40 companies that have achieved a cumulative market capitalization of over $40 Billion.

Interested in American competitiveness and innovation and science education

Interested in assisting refugee families achieve the American Dream.

Larry Bock’s Specialties:

de novo start-ups, entrepreneurship, biotechnology, nanotechnology, smart materials, renewable energy, biofuels, nanotechnology, technology licensing and talent recruitment, strategic partnerships, venture capital, seed capital, innovation, science education, science festivals, San Diego

Larry Bock’s Experience

Judge

UC San Diego Entrepreneur Challenge

(Venture Capital & Private Equity industry)

June 2009 — Present (2 months)
Judge

UC San Diego Entrepreneur Challenge

(Venture Capital & Private Equity industry)

June 2009 — Present (2 months)
Advisor & Judge

BioEASI

(Philanthropy industry)

June 2008 — Present (1 year 2 months)

The gap between the increasingly rapid advances in scientific research and the stationary state of the public’s knowledge in the basic sciences is ever widening. It is becoming more difficult for scientists to convey the significance of their research to the public. Public interest is becoming crucial to deciding the fate of that research. There is a desperate need for new ways to re-ignite the public’s interest and support.

Art is valued universally for its capacity to capture ideas and evoke feelings from people in a way that words cannot. In this faculty, art presents itself as a final resort for making even the most complex issues of science accessible to anyone and everyone. Therefore, the mission of BioEASI is to transform the fruits of scientific research into works of art meant to inspire public interest in science and to direct the funds from art sales into public education and research training.
Advisory Board Member for Chemistry Department

Imperial College London

(Educational Institution; 5001-10,000 employees; Research industry)

June 2008 — Present (1 year 2 months)

http://www3.imperial.ac.uk/chemistry/people/externaladvisoryboard
Xconomist

xConomy

(Privately Held; 1-10 employees; Internet industry)

June 2008 — Present (1 year 2 months)

Xconomy is dedicated to providing business and technology leaders with timely, insightful, close-to-the-scene information about the local personalities, companies, and technological trends that best exemplify today’s high-tech economy.

Xconomy's goalis to become the authoritative voice on the exponential economy, the realm of business and innovation characterized by exponential technological growth and responsible for an increasing share of productivity and overall economic growth.

Xconomy plans to deliver this valuable content through a unique global network of localized blogs, events, conferences, and other initiatives designed to better connect people and ideas.
Inspiration and Executive Director

SAN DIEGO SCIENCE FESTIVAL

(Philanthropy industry)

January 2008 — Present (1 year 7 months)

Join our group: http://www.linkedin.com/e/gis/90792/00B1D174A4C3

The non-profit San Diego Science Festival’s mission is to produce and present the most compelling, exciting, educational and entertaining science gathering on the West Coast, The Inaugural San Diego Science Festival will unite our community to showcase the Science & Innovation that makes Southern California unique! Join us for the first full-scale celebration of Science the West Coast has ever seen! The month-long event celebrates the Science and Innovation all around us with events, lectures, and activities countywide to engage all audiences from students, to teachers, to parents, to science professionals, or anyone that is just curious. If you want to be part of the excitement, join our Group!!
Advisor

www.MySDScience.com

(Civic & Social Organization industry)

January 2008 — Present (1 year 7 months)

Working with a team of UCSD/Salk graduate students and post docs on the creation of a Social Network for Scientists
Advisory Board Member

Cambridge Science Festival

(Non-Profit; 1-10 employees; Philanthropy industry)

2008 — Present (1 year)

National Science Festival in Boston, MA

http://cambridgesciencefestival.org/2007/index.php
Judge WSJ Innovation Awards

Wall Street Jorurnal Innovation Awards

(Venture Capital & Private Equity industry)

March 2008 — Present (1 year 5 months)

Judge at the Wall Street Journal Innovation Awards.
Judge- Entrepreneurship Challenge

Materials Research Society

(Non-Profit; 11-50 employees; Non-Profit Organization Management industry)

2008 — Present (1 year)

Judge material science based business plans for annual competition

http://lucy.mrs.org/entrepreneur/index.html
Seed Investor

ContraFect

(Biotechnology industry)

July 2008 — Present (1 year 1 month)

Infections in the hospital are the 8th leading cause of death in the United States. This occurs primarily because of drug-resistant and newly-emerging pathogens. While bacteria and viruses are treated with antibiotics and antiviral drugs, they have a series of escape mechanisms that come from mutation. Ultimately, all antibiotics become inactive as drug-resistant bacteria arise. In addition, viruses become resistant by mutation and the survival of strains that avoid immune attack. ContraFect Corporation has been formed to address these life threatening infections. Combination therapy will be used to block and disarm virulence factors of bacteria and viruses, rendering them vulnerable to the natural immune balance of the body.
Advisory Board

Arroyo Paseo Charter High School

(Philanthropy industry)

July 2008 — Present (1 year 1 month)

Arroyo Paseo Charter High School is a new start-up charter school based in an urban community of San Diego. The school will enroll 110 students in 2007/08 and have a future maximum enrollment of 250 9th to 12th grade students. The mission of APCHS is to prepare, support and motivate all students, especially students from the diverse urban communities of San Diego, to pursue careers at all levels of science, technology, engineering, and mathematics by providing a rigorous, standards-based, educational program designed to support the academic success of all learners.
Seed Investor

Siluria Technologies, Inc.

(Privately Held; 1-10 employees; Nanotechnology industry)

2007 — Present (2 years)

Provided seed capital for the start of Siluria
EIR

CONNECT

(Venture Capital & Private Equity industry)

September 2007 — Present (1 year 11 months)

Assist start-up entrepreneurs craft their message

http://www.connect.org/programs/springboard/entrepreneurs.htm
Tutor

St. Lukes Refugee Network

(Non-Profit; 11-50 employees; Philanthropy industry)

2007 — Present (2 years)

Tutor Sudanese refugee children in math and science.

The St. Luke's Refugee Network supports families during their years of adjustment to American life by providing help in:

Enrolling children at school Social Security registration Welfare/benefits registration,
Translation for medical visits, official interviews
Registering children at school,
Assistance in obtaining apartments and obtaining employment.
Mentor - Burmese Refugees

Jewish Family Services

(Non-Profit; 11-50 employees; Philanthropy industry)

2007 — Present (2 years)

This is a group of Mentors in the Refugee Resettlement Friendly Match -- a program of Jewish Family Services of San Diego, to help Burmese Refugees integrate into the United States.
Kayak Trainer for Disabled Vets

Team River Running

(Non-Profit; 1-10 employees; Philanthropy industry)

2007 — Present (2 years)

Train disabled veterans to whitewater kayak.

Team River Running's goal is to help veterans recuperating at Walter Reed Army Medical Center (WRAMC) and other military and veterans hospitals around the country find health, healing, and new challenges through whitewater boating. While the focus of Team River Runner's work is on soldiers, TRR also provides water-based recreational opportunities for their family members as well.
Advisor & Seed Investor

ekoVenture

(Internet industry)

2007 — Present (2 years)

Coming in early 2008, ekoVenture is an online adventure travel community bringing together all global tour operators and adventure travelers into one interactive place. ekoVenture allows the adventurer to find all adventure tours that meet their requirements, connect with others like them though a set of interactive experiences, and then book the travel directly on ekoVenture.com.

Core to the ekoVenture brand is the promise to allocate 10% of profits towards environmental sustainability and protection.
Seed Investor

Sapphire Energy

(Oil & Energy industry)

June 2007 — Present (2 years 2 months)

Sapphire’s goal is to be the world’s leading producer of renewable petrochemical products. With Pyle leading the group, the team has built a revolutionary molecular platform that converts sunlight and CO2 into renewable, carbon-neutral alternatives to conventional fossil fuels without the numerous downsides of current biofuel efforts.
Seed Investor

Siluria

(Electrical/Electronic Manufacturing industry)

January 2007 — Present (2 years 7 months)
Co-founder

Genocea Biosciences

(Privately Held; 11-50 employees; Biotechnology industry)

2006 — Present (3 years)

Co-Founder of this company

http://www.genocea.com/

Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. When they work, vaccines are one of the most effective ways of preventing and treating disease. Unfortunately, many research and clinical vaccine programs are hit-and-miss because there is currently no way to screen all possible antigens or predict which ones will work. To remove the guesswork, we need the ability to mimic the human immune system in vitro so one can identify which antigenic epitopes will elicit a competent immune response.

Genocea can rapidly identify antigens that result in the in vivo stimulation of protective CD8+ and CD4+ T-cells, targets that can be immediately incorporated into existing antigen delivery systems to produce multivalent vaccine formulations that have the highest probability of generating protective cell-mediated immunity.
Partner

Bock Family Ventures

(Venture Capital & Private Equity industry)

2006 — Present (3 years)

Seed stage investor in Acceleron Pharma (Private – metabolic and musculoskeletal diseases), Cambrios (Priviae – high performance electronic materials), Magen Biosciences (Private – dermatology and skin care), Plexikon Pharmaceuticals (Private – scaffold based drug design) Poland Partners (Private - a $62.5M venture capital fund investing in Central Europe), Saphire Energy (Private – biofuels), and Siluria Technologies Inc. (Private - biologyy directed electronic assembly) and Sirtris Pharmaceticals (NASDAQ: SIRT – gene regulation).
Seed Investor

Cambrios

(Privately Held; 11-50 employees; Biotechnology industry)

2004 — Present (5 years)

Provided seed capital for the start of Cambrios

http://www.cambrios.com/

Cambrios is currently focused on the development of electronic materials for the display industry. Cambrios proprietary nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components at lower manufacturing cost. The company’s first product, a directly patternable, wet-processable transparent conductive film, is poised to replace the industry standard sputtered indium tin oxide (ITO). Subsequent products will leverage this technology to produce other functional films for display and thin films applications.
Director

FEI Company

(Public Company; 1001-5000 employees; FEIC; Nanotechnology industry)

January 2004 — Present (5 years 7 months)

Board Member and Member of the Compensation Committee, Strategy Committees

http://www.fei.com

From the world's first DualBeam™ system, to market-leading scanning electron microscopes, to the world's most powerful, commercially-available transmission electron microscope, FEI's Tools for Nanotech are enabling researchers, scientists, and industrial pioneers to see, analyze, and manipulate two- and three-dimensional nanoscale structures. Our market-leading instruments, which include scanning electron microscopes, transmission electron microscopes, Dualbeam™ systems, and focused ion beam tools, push the boundaries of discovery and exploration, facilitating breakthroughs in pharmacology, biotechnology, forensics, pathology, materials science, semiconductor manufacturing and data storage.
Founder and Initial Executive Chairman and CEO

Nanosys Inc.

(Privately Held; 51-200 employees; Nanotechnology industry)

2003 — Present (6 years)

Original Founder and Initial CEO and Executive Chairman of this company

http://www.nanosysinc.com

Founded in 2001 by an experienced business team and world-renowned nanotechnology leaders, Nanosys is an industry-leading nanotechnology company developing, manufacturing and selling products based on a technology platform of high performance inorganic nanostructures. Nanosys' technology is covered by a portfolio of over 500 patents and patent applications that is currently being applied to opportunities in multiple industries including energy, electronics, optoelectronics, life science, and defense. Current application areas of Nanosys technology include flat-panel displays, non-volatile memory, fuel cells, solid-state lighting, chemical analysis chips and medical devices.
Limited Partner

Venrock Associates

(Partnership; 11-50 employees; Venture Capital & Private Equity industry)

2003 — Present (6 years)

Limited Partner in Venrock's Entrepreneurs side fund

http://www.venrock.com

Venrock is a premier venture capital firm with offices in Menlo Park, New York, Cambridge, MA, and Israel. Originally established as the venture capital arm of the Rockefeller family, Venrock continues a seven-decade tradition of partnering with entrepreneurs to establish successful, enduring companies. Having invested $1.9 billion in 405 companies resulting in 124 IPOs and 114 M&A exits over the past 38 years, Venrock's investment returns place it among the top tier venture capital firms that have achieved consistently superior performance. With a primary focus on technology, healthcare, and energy, portfolio companies have included Apple Computer, Centocor, Check Point Software, DoubleClick, Gilead Sciences, Idec Pharmaceuticals, Illumina, Intel, Millennium Pharmaceuticals, Sirna Therapeutics, and StrataCom.
Seed Investor

Acceleron Pharma

(Privately Held; 11-50 employees; Biotechnology industry)

2003 — Present (6 years)

Provided seed capital for launch of Acceleron Pharma

http://www.acceleronpharma.com

Since its initial financing in 2004, Acceleron’s goal has been to develop innovative therapies. Acceleron has built in-house drug development capabilities, allowing it to focus its creativity and innovation on the biology of the GDF protein family, while streamlining the development of novel therapies.

This strategy has already yielded a rich pipeline of compounds that have the potential to be therapeutic breakthroughs for a number of devastating diseases. Acceleron's approach has opened a completely new area of GDF-targeted therapies that can modulate the growth and repair of a variety of tissue systems, offering new hope and benefits to patients.
Special Limited Partner

Lux Capital

(Partnership; 11-50 employees; Nanotechnology industry)

2003 — Present (6 years)

http://www.luxcapital.com/

Lux Capital Management is a research-driven investment firm focused on de novo, seed and early stage investments in the physical and life sciences. Lux takes an active role in helping management teams build successful businesses in high growth sectors. Our investment team has built over 20 companies from scratch.
Scientific Advisory Board

Protia

(Privately Held; 1-10 employees; Biotechnology industry)

2003 — Present (6 years)

Protia utilizes a new discovery with which we chemically modify existing, pharmaceuticals to create new, patentable derivatives of those pharmaceuticals. Protia's technology is the only way in which the size of drug molecules can be made smaller. The properties of Protia-modified drugs will change the beneficial bioactivity of these drugs in subtle ways, but in ways that should not change their toxicity or bioavailability properties. Furthermore, the manufacture of Protia-modified drugs will benefit by utilizing existing plants and production methods. The modest increase in manufacturing cost will be far offset by the ability to obtain new patents. Protia has already obtained an Allowance from the USPTO on our first patent application. Subsequently, Protia has filed pending patent applications on the 240 small molecule drugs predicted each to earn annually more than $500MM. In the best case scenario, that makes the potential market for Protia's IP exceed $120B annually.
Memberof Advisory Board

PECSEA

(Government Agency; 11-50 employees; Government Administration industry)

2003 — Present (6 years)

Fp\ocused on nanotechnology export administration

http://www.ita.doc.gov/td/pec/index.html

PECSEA- President's Export Council Subcommittee on Export Administration. A subcommittee of the President's Export Council. The PECSEA is an advisory committee whose members are appointed by the Secretary of Commerce to advise the U.S. Government on matters and issues pertinent to implementation of the provisions of the Export Administration Act (EAA) and the Export Administration Regulations (EAR). The PECSEA is composed primarily of representatives from the private sector.
Seed Investor

Sirtris Pharmaceuticals

(Public Company; 11-50 employees; SIRT; Biotechnology industry)

2002 — Present (7 years)

Provided seed capital for the start of Sirtris Pharmaceuticals

Sirtris was bought by Glaxo Wellcome for $750M

http://www.sirtrispharma.com/

Sirtris Pharmaceuticals™ (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company's headquarters are in Cambridge, Massachusetts
Seed Investor

Plexxikon

(Privately Held; 11-50 employees; Biotechnology industry)

2000 — Present (9 years)

Provided seed capital for the start of Plexxikon

http://www.plexxikon.com

Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas, including metabolic disease, oncology, inflammation, CNS and cardiovascular disease.

With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process within various families of drug targets. .

Plexxikon’s business strategy is to generate competitively differentiated drug candidates across multiple therapeutic areas, then partner at the IND or early clinical stage for further co-development and commercialization.
Co-founder

Fast Track Systems

(Privately Held; 11-50 employees; Biotechnology industry)

2000 — Present (9 years)

Co-founded this company focused on accelerating clinical development

http://www.fast-track.com

As a world-class provider of clinical trial software and professional services to pharmaceutical and biotechnology companies, Fast Track Systems, Inc., provides a true competitive edge in the clinical development process through authoring protocols; planning, negotiating, or managing trial budgets; seeking to drastically reduce trial cycle times; and/or needing to maintain strict fiscal responsibility.

Fast Track’s global cost and procedure benchmarking databases; drawn from over 240,000 negotiated investigator agreements, 25,000 finalized protocols and 3,000 CRO contracts, have been the most relevant industry resource for over 14 years. Over 50 of the top pharmaceutical companies rely on our products to enable clinical researchers, finance staff and medical management to efficiently collaborate in making informed decisions that influence the execution of the final clinical plan.
General Partner

CW Group

(Partnership; 1-10 employees; Venture Capital & Private Equity industry)

1999 — Present (10 years)

Seed and early stage healthcare venture capital fund

http://www.cwventures.com/

CW Group, a leading manager of medical venture capital funds focused on seed and early stage healthcare investing, welcomes you to our Web Site.

CW Group invests in seed and early stage healthcare companies which have the potential to grow rapidly into substantial enterprises. CW Group invests primarily in companies it co-founds with leading scientists and entrepreneurs in the areas of biotechnology, including pharmaceuticals, genomics and diagnostics; medical devices and instrumentation; healthcare services and medical information systems.

CW Group has managed seven medical venture capital funds, and since 1982 has invested in the early financing of over 70 companies. CW Group's limited partners include major corporations, pension funds, endowment funds, financial institutions, and private investors.
Founder

Illumina Inc.

(Public Company; 201-500 employees; ILMN; Biotechnology industry)

1999 — Present (10 years)

Original Founder of this company

http://www.illumina.com

Illumina’s mission is to develop next-generation tools for the large-scale analysis of genetic variation and function, the results of which will pave the way for personalized medicine, a key goal of genomics and proteomics.

Illumina's goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Co-founder

Conforma Therapeutics

(Public Company; 51-200 employees; PFE; Biotechnology industry)

1998 — Present (11 years)

Co-founder of this company that was acquired by Pfizer for $250 million.

Conforma Therapeutics (acquired by Pfizer) , a San Diego-based biopharmaceutical company, was focused on the design and development of novel drugs for the treatment of cancer. Conforma’s internal discovery efforts have been focused on drugs that target the cellular HSP90 family of molecular "chaperones" that control protein
shape or conformation, including that of key signaling molecules involved in the growth and survival of tumor cells. HSP90-directed drugs selectively induce the degradation of these cancer-promoting proteins,
leading to tumor cell death. Conforma is conducting Phase I clinical trials with its lead HSP90 product, CNF1010, for the treatment of cancer and plans to initiate clinical testing of its second, orally administered HSP90 product, CNF2024, in the third quarter of 2005.
Seed Investor

Surface Logix

(Privately Held; 11-50 employees; Biotechnology industry)

1998 — Present (11 years)

Provided seed capital for the start of Surface Logix

http://www.surfacelogix.com

Surface Logix Inc. uses its expertise in biophysical chemistry to create new small molecule drugs that are optimized to meet the challenges of human physiology. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases.
Co-founder

Community Cousins

(Non-Profit; 1-10 employees; Civic & Social Organization industry)

1995 — Present (14 years)

Founded with wife, Community Cousins, a non-profit foundation focused on breaking down racial barriers, that was selected by former Vice President Al Gore as one of ten outstanding grass root efforts nationally.
Seed Investor

Spectral Genomics

(Nanotechnology industry)

1995 — Present (14 years)
Founder and Initial CEO

Argonaut ~Technologies

(Public Company; 201-500 employees; BIOT; Biotechnology industry)

1994 — Present (15 years)

Original Founder and Initial CEO of this Argonaut that went public and subsequently merged with Biotage

http://www.biotage.com

Biotage AB is a global company providing innovative solutions, knowledge and experience in the areas of medicinal and analytical chemistry, process development and genetic analysis. The company’s strengths include revolutionary high-quality technologies, a broad business base and a long-term view of the market.

Biotage intends to continue expanding its business and product portfolio. The company aims to help its global customers meet the enormous pressures of time, cost and innovation. Its mission is to lead customers successfully into the next era of research, discovery and development with its solutions and services.
Co-founder

Aurorra Biosciences

(Privately Held; 1001-5000 employees; VRTX; Biotechnology industry)

1994 — Present (15 years)

Co-founder of this company that went public and was subsequently acquired by Vertex Pharmaceuticals for $700 million.

http://www.vpharm.com/

Aurora Biosciences Corporation (acquired by Vertex) designs, develops and commercializes proprietary drug discovery systems, services and technologies to accelerate and enhance the discovery of new medicines. Aurora is developing a proprietary, ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation and informatics. Aurora believes its integrated platform will shorten the time required to identify high quality lead compounds and to optimize those compounds into drug development candidates.
Founder and Initial CEO

IDUN Pharmaceuticals

(Privately Held; 201-500 employees; PFE; Biotechnology industry)

1993 — Present (16 years)

Original Founder and Initial CEO of this company that was acquired by Pfizer for $250 million

Idun Pharmaceuticals, Inc. (acquired by Pfizer) was a privately-held biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the areas of liver disease, inflammation, and cancer. Idun's lead product candidate, IDN-6556, is in clinical studies for both liver transplantation and in patients infected with Hepatitis C virus. The company has a number of product candidates in advanced preclinical development for inflammation and cancer. Idun has an extensive patent portfolio comprised of 145 issued patents worldwide. Idun's corporate headquarters and research and development facility was located in San Diego, California.
Founder and Initial CEO

Caliper Life Sciences

(Public Company; 201-500 employees; CALP; Biotechnology industry)

1992 — Present (17 years)

Original Founder and Initial CEO of this company

http://www.caliperls.com

Caliper Life Sciences combines microfluidics, liquid handling and laboratory automation to deliver unique research tools for today’s Drug Discovery and Development and Genomics and Proteomics laboratories. We manufacture and sell products such as the LabChip 3000 Drug Discovery system, Caliper Sciclone liquid handler, Staccato Assay Workstations, and the LabChip 90 Automated Electrophoresis system. Each of these products addresses critical applications within the life sciences industry; each of these applications is on the critical path to improving human health.
Founder

Onyx Pharmaceuticals

(Public Company; 501-1000 employees; ONXX; Biotechnology industry)

1992 — Present (17 years)

Co-founder and Initial investor in Onyx Pharmaceuticals

http://www.onyx-pharm.com

Onyx Pharmaceuticals is developing innovative small molecule cancer treatments based on a molecular understanding of cancer. Onyx lead product is Nexavar® (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis (the formation of new blood vessels to support cancer cell growth). This product is being marketed in collaboration with Bayer HealthCare Pharmaceuticals.

Nexavar is approved in more than 60 countries for the treatment of patients with advanced kidney cancer. In addition, we were recently granted approval in a second indication, liver cancer, in the U.S. and E.U.

Onyx also have a second product in clinical testing, a small molecule cell cycle inhibitor that resulted from a collaboration with Pfizer, which is responsible for developing the drug.
Seed Investor

River Medical

(Privately Held; 201-500 employees; AMI; Medical Devices industry)

1992 — Present (17 years)

Seed Investor in River Medical which did an LBO of IVAC and was subsequently acquired by IMED to become Alaris Medical.
Seed Investor

Sequana Therapeutics

(Public Company; 51-200 employees; sqna; Biotechnology industry)

1992 — Present (17 years)

Inital investor in Sequana Therapeutics

Sequana Therapeutics was a leading genomics company that uses industrial-scale gene finding technologies and functional genomics to develop products aimed at diagnosing and treating common human diseases

Arris Pharamceuticals acquired Sequana Therapeutics in 1997 to become Axys Pharmaceuticals. Axys went on to form Axys Advanced Technologies, which got bought by ChemRx, becoming ChemRx Advanced Technologies. Axys was bought by Celera Genomics and now operates as Celera.
Seed Investor

Microcide Pharmaceuticals

(Biotechnology industry)

1992 — Present (17 years)
Founder and Initial CEO

Pharmacopeia

(Public Company; 201-500 employees; PCOP; Biotechnology industry)

1991 — Present (18 years)

Original Founder of this company

http://www.pharmacopeia.com

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or with partners including seven clinical compounds in Phase 2 or Phase 1 development addressing hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The company is leveraging its fully integrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Organon, Schering-Plough, and Wyeth Pharmaceuticals.
Founder

ARIAD Pharmaceticals

(Biotechnology industry)

1989 — Present (20 years)

Original Founder of this company

http://www.ariad.com/

ARIAD is developing breakthrough medicines that regulate cell-signaling pathways implicated in cancer. ARIAD's pipeline includes a series of small molecule product candidates that provide targeted and highly potent anti-cancer activity to treat solid tumors and hematologic cancers, as well as the spread of tumors to distant sites. Our lead candidate — deforolimus, a novel mTOR inhibitor — has been given fast track designation by the FDA for the treatment of soft-tissue and bone sarcomas.
Founder and Initial CEO

Neurocrine Biosciences

(Public Company; 201-500 employees; NBIX; Biotechnology industry)

1989 — Present (20 years)

Original Founder and Initial CEO of this company

http://www.neurocrine.com

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine-related diseases.

Neurocrine's product address markets including insomnia, anxiety, depression, irritable bowel syndrome and pain.

Neurocrine currently has multiple programs in development. Several of these programs have advanced into clinical trials. Indiplon, for the treatment of insomnia, is being discussed with the FDA for resubmission for approval. Neurocrine has completed a Phase II trial with GnRH for the treatment of endometriosis Neurocrine is evaluating its proprietary compound, urocortin 2 in a Phase II clinical development in patients with congestive heart failure. The Company's CRF program, partnered with GlaxoSmithKline, is continuing to develop multiple compounds in Phase I and Phase II clinical trials for anxiety/depression and irritable bowel syndrome (IBS).
Founder and Initial CEO

Metra Biosystems

(Public Company; 501-1000 employees; QDEL; Biotechnology industry)

1988 — Present (21 years)

Original Founder and Initial CEO of this company that went public and was subsequently acquired by Quidel

http://www.quidel.com

Quidel Corporation (Nasdaq: QDEL) is a leader serving to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health.
Co-founder

Vertex Pharmaceuticals

(Public Company; 1001-5000 employees; VRTX; Biotechnology industry)

1987 — Present (22 years)

Co-founder of this company
Co-founder

GenPharm International

(Privately Held; 11-50 employees; Biotechnology industry)

1986 — Present (23 years)

Co-founder of GenPharm International and spinout company Pharming...GenPharm was acquired by Medarex
First Round Investor

Viagene

(Privately Held; 51-200 employees; Biotechnology industry)

1986 — Present (23 years)
First Round Investor

Gensia Pharmaceuticals

(Public Company; 51-200 employees; Biotechnology industry)

1986 — Present (23 years)
Second Round Investor

IDEC Pharmaceuticals

(Public Company; 1001-5000 employees; BIIB; Biotechnology industry)

1986 — Present (23 years)
First Round Investor

Biosym Technologies

(Privately Held; 51-200 employees; Biotechnology industry)

1986 — Present (23 years)

First round investor in Biosym.

Biosym was acquired by Corning for $250M.

It was later spun out as Molecular Simulations and was subsequently acquired by Pharmacopeia. Pharmacopeia spun it out as Accelrys..

Accelrys develops and commercializes Scientific Business Intelligence software for the integration, mining, analysis, modeling and simulation, management and interactive reporting of scientific data. Accelrys solutions are used by biologists, chemists, materials scientists, and information technology professionals for product design as well as drug discovery and development. Accelrys technology and services are designed to meet the needs of today’s leading research and development organizations.
First Round Investor

Cytotech

(Privately Held; 11-50 employees; Biotechnology industry)

1986 — Present (23 years)
Co-founder

Athena Neurosciences

(Public Company; 5001-10,000 employees; ELNCF; Biotechnology industry)

1985 — Present (24 years)

Original Founder of this company that went public and was acquired by Elan Pharmaceuticals for $625 million.

Athena Neuroscience is a pharmaceutical company committed to the field of neurology focusing on Alzheimer's disease. Athena Neurosciences went public under the stock symbol: ATHN and was subsequently acquired by Elan Corp for $ 625M
Husband

The Bock Family

(Partnership; 1-10 employees; Professional Training & Coaching industry)

1985 — Present (24 years)
First Round Investor

Gen-Probe

(Public Company; Nanotechnology industry)

1985 — Present (24 years)
Second Round Investor

GenProbe

(Public Company; 201-500 employees; Biotechnology industry)

1985 — Present (24 years)

Second Round investor in Gen Probe

http://www.gen-probe.com

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 24 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people.
General Partner

Avalon Ventures

(Partnership; 1-10 employees; Venture Capital & Private Equity industry)

June 1988 — January 1997 (8 years 8 months)

De novo seed start-up venture capital fund and early stage investor in River Medical (Private – drug delivery, purchased IVAC from Eli Lily in an LBO and did a $700M merger with IMED to form Alaris Medical (NASDAQ: AMI – medical devices)), Sequana Therapeutics (NASDAQ: SQNA - genomics, merged with Arris Pharmaceuticals to form AXYS Pharmaceuticals (NASDAQ: AXPH) and subsequently acquired by Celera Genomics (NASDAQ: CRA)), Software Transformation (Private – object based software programming, acquired by Novell (NASDAQ: NOVL) for $25M), Surface Logix (Private – nano- imprint lithography), and Talarian (NASDAQ: TALR – real time, high content information processing over distributed networks merged with TIBCO (NASDAQ: TIBX)).
Associate

Fairfield Ventures

(Partnership; 1-10 employees; Venture Capital & Private Equity industry)

1985 — 1988 (3 years)

Early stage venture investor in Biosym Technologies (Private – computer-aided-drug discovery – acquired by Corning (NYSE: GLW) for $250M)) Gen-Probe (NASDAQ: GNPR – DNA diagnostics, acquired by Chugai Pharmaceuticals for $180M), Gensia Pharmaceuticals (NASDAQ: GNSA – cardiovascular drugs, merged with Sicor to become Gensia-Sicor and subsequently acquired by TEVA Pharmaceuticals (NASDAQ: TEVA)), IDEC Pharmaceuticals (NASDAQ: IDEC – monoclonal antibody therapy, merged with Biogen to become Biogen Idec (NASDAQ: BIIB)), Oclassen Pharmaceuticals (Private - dermatology, acquired by Watson Pharmaceuticals (NYSE: WPI) for $180M), and Viagene (Private – gene therapy, acquired by Chiron Corporation for $100M).
Student

UCLA Anderson School of Management

(Educational Institution; 1001-5000 employees; Higher Education industry)

September 1984 — May 1985 (9 months)

Jim is the ideal field study partner and person to spend the consulting overpayment fees with.
Summer Intern

Burr, Egan and Deleage

(Partnership; 1-10 employees; Venture Capital & Private Equity industry)

1984 — 1985 (1 year)

Summer intern at this high technology venture capital fund
Research Associate

Genentech, Inc.

(Public Company; 10,001 or more employees; gene; Biotechnology industry)

1980 — 1983 (3 years)

Started career as a Researcher in the early days at Genentech, Inc. in the field of infectious diseases, where he was on the team that received the AAAS Newcomb Cleveland Prize for demonstrating the world’s first recombinant DNA vaccine.
Student

Bowdoin College

(Educational Institution; 501-1000 employees; Higher Education industry)

1977 — 1981 (4 years)

Larry Bock’s Education

University of California, Los Angeles - The Anderson School of Management

MBA , Finance/Entrepreneurial Studies , 1982 — 1985

Activities and Societies:

Entrepreneur Society, Venture Capital Fellows
Horace Greeley High School

HS , 1974 — 1982
Bowdoin College

BA , Biochemistry , 1977 — 1981

Activities and Societies:

Molecular Biolog Society, Film Society, Outing Club
Bowdoin College

B.A. , 1977 — 1981

Additional Information

Larry Bock’s Websites:

Larry Bock’s Interests:

nanotechnology, biotechnology, education, entrepreneurship, venture capital, skiing, whitewater kayaking, digital video editing, international travel

Larry Bock’s Groups:

Advisory Board - NanoBusiness Alliance, Technology Advisory Board - NanoBusiness Alliance, Environmental Health and Safety Advisory Board NanoBusiness Alliance, President’s Export Council Subcommittee on Export Administration (PECSEA), Nanotechnology Technical Advisory Group (NTAG) reporting to the President’s Council of Advisors on Science and Technology (PCAST), Blue Ribbon Task Force on Nanotechnology, Advisory Board of the Faculty of Chemistry at the University of California, Berkeley, Editorial Board of the Journal of Nano Education

UCLA Anderson Alumni Network
On Startups - The Community For Entrepreneurs
SoCal Science Cafe: Career Cafe
Genentech Employees and Alumni
Small Cap Investors
CleanTech Network
San Diego Science Festival (SDSF)
Advanced Scientific Communities (TM)
Mad4iPhone - The official iPhone users group -
UC San Diego Entrepreneur Challenge
Pharmacopeia Inc. Alumni
CleanTALK San Diego
CONNECT - Springboard
MySDscience - San Diego Science Network

Larry Bock’s Honors:

Venture Capital Journal - Ten Most Influential Venture Capitalists, Red Herring - Top Ten Innovators, Forbes-Wolfe NanoReport - Number One Powerbroker in Nanotechnology, Ernst & Young - Finalist for Entrepreneur of the Year, Small Times - Innovator of the Year and Top 3 Business Leaders of the Year, Einstein Award by the Jerusalem Foundation, World Economic Forum Technology Pioneers Award, Red Herring Top 100, Scientific American’s Nifty Fifty, Science Magazine’s Technology Breakthrough of the Year, World Technology Network’s Leading Company in Material Science.

Larry Bock’s Contact Settings

Interested In:

career opportunities
consulting offers
new ventures
job inquiries
expertise requests
business deals
reference requests
getting back in touch

View Full Profile

Larry Bock’s Summary

Larry Bock’s Specialties:

Larry Bock’s Experience

Judge

UC San Diego Entrepreneur Challenge

Judge

UC San Diego Entrepreneur Challenge

Advisor & Judge

BioEASI

Advisory Board Member for Chemistry Department

Xconomist

Inspiration and Executive Director

SAN DIEGO SCIENCE FESTIVAL

Advisor

www.MySDScience.com

Advisory Board Member

Cambridge Science Festival

Judge WSJ Innovation Awards

Wall Street Jorurnal Innovation Awards

Judge- Entrepreneurship Challenge

Seed Investor

ContraFect

Advisory Board

Arroyo Paseo Charter High School

Seed Investor

Siluria Technologies, Inc.

EIR

CONNECT

Tutor

St. Lukes Refugee Network

Mentor - Burmese Refugees

Kayak Trainer for Disabled Vets

Team River Running

Advisor & Seed Investor

ekoVenture

Seed Investor

Sapphire Energy

Seed Investor

Siluria

Co-founder

Partner

Bock Family Ventures

Seed Investor

Cambrios

Director

Founder and Initial Executive Chairman and CEO

Nanosys Inc.

Limited Partner

Seed Investor

Special Limited Partner

Lux Capital

Scientific Advisory Board

Protia

Memberof Advisory Board

PECSEA

Seed Investor

Seed Investor

Co-founder

General Partner

CW Group

Founder

Co-founder

Seed Investor

Co-founder

Community Cousins

Seed Investor

Founder and Initial CEO

Co-founder

Aurorra Biosciences

Founder and Initial CEO

IDUN Pharmaceuticals

Founder and Initial CEO

Founder

Seed Investor

River Medical

Seed Investor

Sequana Therapeutics

Seed Investor

Microcide Pharmaceuticals